Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers By Ogkologos - February 19, 2025 632 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the eNRGy study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells November 21, 2023 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights... December 22, 2025 Load more HOT NEWS Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms
